What is the clinical evidence on psilocybin for the treatment of psychiatric disorders? A systematic review
Open accessThe DOI matches its Crossref record; 67 of the 68 references it cites were found in a registry or an index.
Abstract
Background: Psilocybin is a predominant agonist of 5HT 1A and 5HT 2A/C receptors and was first isolated in 1958, shortly before it became a controlled substance. Research on the potential therapeutic effects of this compound has recently re-emerged alongside what is being addressed as a psychedelic renaissance. Methods: In this paper we performed a systematic review of the clinical trials conducted so far regarding the therapeutic effects of psilocybin on psychiatric disorders. The eligibility criteria included clinical trials that assessed psilocybin's potential therapeutic effects on patients with psychiatric disorders. Nine hundred seven articles were found and screened in regard to the title, from which 94 were screened through abstract and 9 met the eligibility criteria and were included. Results: The papers published focused on 3 disorders: depression, obsessive-compulsive disorder (OCD) and substance use disorder (namely tobacco and alcohol). Psilocybin has shown a relatively safe profile and very promising results, with reductions found on most of the psychiatric rating scales’ scores. Research on depression showed the most solid evidence, supported by 3 randomized controlled trials. Studies on OCD and substance use disorder showed more limitations due to their open-label design. Conclusions: Altogether, the results from the studies reviewed in this paper suggest a substantial therapeutic potential. This calls for further research to confirm the results observed so far and further explain the underlying mechanisms.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Although psychedelic therapies have demonstrated outstanding benefits in several clinical trials”
From Psychedelics and Other Psychoplastogens for Treating Mental Illness. (2021) · cites this paper as [290]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Hospital Anxiety and Depression Scale
Zigmond, A. S., & Snaith, R. P. (1983) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1983.tb09716.x · Cited by 47,139
An inventory for measuring depression
BECK, A. T. (1961) · Archives of General Psychiatry · doi:10.1001/archpsyc.1961.01710120031004 · Cited by 38,032 · cited 2×
“Primary outcome measures were assessed with self-reports on: STAI(20) of State (STAI-S) and of Trait (STAI-T) subscales; Hospital Anxiety and Depression Scale (HADS)(22) subscales of anxiety (HADS-A), depression (HADS-D) and total (HAD-T); and BDI.(18) No serious adverse events were reported.”
MethodDepression and quality of life in older persons: A review
Sivertsen, H., Bjørkløf, G. H., Engedal, K., Selbæk, G., & Helvik, A.-S. (2015) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000437299 · Cited by 14,152
Molecular Mechanisms of Depression: Perspectives on New Treatment Strategies
Lang, U. E., & Borgwardt, S. (2013) · Cellular Physiology and Biochemistry · doi:10.1159/000350094 · Cited by 8,475
Scoville, W. B. (1949) · Journal of neurosurgery · doi:10.3171/jns.1949.6.1.0065 · Cited by 7,380
A Meta-Analysis of Cytokines in Major Depression
Dowlati, Y., Herrmann, N., Swardfager, W., Liu, H., Sham, L., Reim, E. K., & Lanctôt, K. L. (2010) · Biological Psychiatry · doi:10.1016/j.biopsych.2009.09.033 · Cited by 4,729 · cited 1×
“Some authors(59) propose that one of the mechanisms through which psilocybin improves depression symptoms is by blocking the activity of inflammatory cytokines, namely TNF-a, whose levels have been found to be significantly higher in depressed patients.(60) Research with fMRI in healthy volunteers after psilocybin adm…”
BackgroundRush, A. J., Trivedi, M. H., Ibrahim, H. M., Carmody, T. J., Arnow, B., Klein, D. N., Markowitz, J. C., Ninan, P. T., Kornstein, S., Manber, R., et al. (2003) · Biological Psychiatry · doi:10.1016/s0006-3223(02)01866-8 · Cited by 3,829
Drevets, W. C., Price, J. L., & Furey, M. L. (2008) · Brain Structure and Function · doi:10.1007/s00429-008-0189-x · Cited by 2,241
Griffiths, R. R., Johnson, M. W., Carducci, M. A., Umbricht, A., Richards, W. A., Richards, B. D., Cosimano, M. P., & Klinedinst, M. A. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881116675513 · Cited by 2,201 · cited 1×
“The best option seems to be the use of an inactive low dose of psilocybin, as it showed some protection against monitor expectancy and it assures the benefit of the instruction that psilocybin is going to be administered on each session.(27) Additionally, because psilocybin administration was associated with psycholog…”
BackgroundA scale for the assessment of hedonic tone the Snaith-Hamilton pleasure scale
Snaith, R. P., Hamilton, M., Morley, S., Humayan, A., Hargreaves, D., & Trigwell, P. (1995) · British Journal of Psychiatry · doi:10.1192/bjp.167.1.99 · Cited by 1,778
Research works printed but not linked: 1
- Johnson, 2014, Pilot study of the 5-HT2AR agonist psilocybin in the treatment of tobacco addiction, J Psychopharmacol (Oxford, England) [Internet]., 28, 0269881114548296-
Cited by
Psychedelics and Other Psychoplastogens for Treating Mental Illness.
Vargas, M. V., Meyer, R., Avanes, A. A., Rus, M., & Olson, D. E. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.727117 · Cited by 166
Efficacy of psilocybin for treating symptoms of depression: systematic review and meta-analysis
Metaxa, A.-M., & Clarke, M. J. (2024) · BMJ · doi:10.1136/bmj-2023-078084 · Cited by 120
“29-32 Lastly, systematic reviews did not consider grey literature, 33 34 which might have led to a substantial overestimation of psilocybin’s efficacy as a treatment for depression.”
BackgroundDrug-drug interactions between psychiatric medications and MDMA or psilocybin: a systematic review
Sarparast, A., Thomas, K., Malcolm, B., & Stauffer, C. S. (2022) · Psychopharmacology · doi:10.1007/s00213-022-06083-y · Cited by 88
Trends in drug use among nightclub and festival attendees in New York City, 2017-2022
Palamar, J. J., Le, A., Cleland, C. M., & Keyes, K. M. (2023) · International Journal of Drug Policy · doi:10.1016/j.drugpo.2023.104001 · Cited by 56
Pepe, M., Hesami, M., de la Cerda, K. A., Perreault, M. L., Hsiang, T., & Jones, A. M. P. (2023) · Biotechnology Advances · doi:10.1016/j.biotechadv.2023.108247 · Cited by 36
Metadata
- Authors
- Castro Santos, H., & Gama Marques, J.
- Affiliations
- Hospital Júlio de Matos, Centro Hospitalar Psiquiátrico de Lisboa
- Venue
- Porto Biomedical Journal
- Published
- 2021-01
- Volume
- 6
- Issue
- 1
- Pages
- e128
- ISSN
- 2444-8664 (ISSN-L)
- PMC
- PMC8055489
- OpenAlex
- W3133450788
- Cited by
- 37
- References
- 68
- Citations by year
- 2026: 3 · 2025: 8 · 2024: 10 · 2023: 10 · 2022: 3 · 2021: 3
- FWCI
- 0.86
- Type
- journal article
- Language
- en
- Open access
- diamond
- doi.org
- Locations
- Porto Biomedical Journal (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Topics
- Social Sciences › Psychology › Clinical Psychology › Psychedelics and Drug Studies
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Social Sciences › Health › Religion, Spirituality, and Psychology
- Keywords
- psilocybin, psychedelic therapy, mental illness, depression, obsessive-compulsive disorder, substance use disorders, tobacco use, alcohol consumption, treatment efficacy, safety profile
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: What is the clinical evidence on psilocybin for the treatment of psychiatric disorders? A systematic review. https://app.cochat.ai/papers/10.1097/j.pbj.0000000000000128
- The paper
- Castro Santos, H., & Gama Marques, J. (2021). What is the clinical evidence on psilocybin for the treatment of psychiatric disorders? A systematic review. Porto Biomedical Journal. https://doi.org/10.1097/j.pbj.0000000000000128
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
